Pfizer for Professionals Pfizer for Professionals




Pfizer Medical Information
(Search Medical Responses)
WyethHCP.com
(Access Wyeth for Professionals)
Explore Other Online Resources
ppn-vr-sso-links.htm
To report an adverse event or to speak to a member of Pfizer Medical Information, please call 1-800-438-1985

Share Your Feedback
Prescribing Information
ARICEPT® (donepezil hydrochloride) Tablets/ARICEPT® ODT (donepezil hydrochloride) Orally Disintegrating Tablets
How Supplied
Return to the Aricept Product Center

Comp

ARICEPT® is supplied as film-coated, round tablets containing either 5 mg or 10 mg of donepezil hydrochloride.

The 5 mg tablets are white. The strength, in mg (5), is debossed on one side and ARICEPT® is debossed on the other side.

The 10 mg tablets are yellow. The strength, in mg (10), is debossed on one side and ARICEPT® is debossed on the other side.

 

5 mg (White) Bottles of 30 (NDC# 62856-245-30)
  Bottles of 90 (NDC# 62856-245-90)
  Unit Dose Blister Package 100 (10x10)
  (NDC# 62856-245-41)

 

10 mg (Yellow) Bottles of 30 (NDC# 62856-246-30)
  Bottles of 90 (NDC# 62856-246-90)
  Unit Dose Blister Package 100 (10x10)
  (NDC# 62856-246-41)

ARICEPT® ODT is supplied as tablets containing either 5 mg or 10 mg of donepezil hydrochloride.

The 5 mg orally disintegrating tablets are white. The strength, in mg (5), is embossed on one side and ARICEPT® is embossed on the other side.

The 10 mg orally disintegrating tablets are yellow. The strength, in mg (10), is embossed on one side and ARICEPT® is embossed on the other side.

 

5 mg (White) Unit Dose Blister Package 30 (10x3)
  (NDC# 62856-831-30)

 

10 mg (Yellow) Unit Dose Blister Package 30 (10x3)
  (NDC# 62856-832-30)

Storage: Store at controlled room temperature, 15°C to 30°C (59°F to 86°F).

RX only

ARICEPT® is a registered trademark of Eisai Co., Ltd.
Manufactured and Marketed by Eisai Inc., Teaneck, NJ 07666
Marketed by Pfizer Inc, New York, NY 10017


ARICEPT Safety Information
 

Important Safety Information

Cholinesterase inhibitors have the potential to increase gastric acid secretion. Patients at risk for developing ulcers, including those receiving concurrent NSAIDs, should be monitored closely for gastrointestinal bleeding.

In clinical trials, syncopal episodes have been reported (2% for ARICEPT versus 1% for placebo).

In clinical trials, the most common adverse events seen with ARICEPT were nausea, diarrhea, insomnia, vomiting, muscle cramps, fatigue, anorexia, and ecchymosis. In studies, these were usually mild and transient.

SetPProProdListVar.htm
SetPFPGroupVar.htm